Companies / Jade Biosciences, Inc. / Activity
Activity — Jade Biosciences, Inc.
9 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Frohlich Tom CEO | Grant | Common Stock | $0 | +79K +1038.78% | 86,331 0.14% of shares | low |
| Feb 12, 2026 | King Andrew James Executive | Grant | Common Stock | $0 | +41K +11.96% | 386,113 0.61% of shares | low |
| Feb 12, 2026 | Dahms Bradford D. Executive | Grant | Common Stock | $0 | +38K | 37,813 0.06% of shares | low |
| Feb 12, 2026 | Balta Elizabeth Executive | Grant | Common Stock | $0 | +28K | 28,125 0.04% of shares | low |
| Jun 9, 2026 | Dobmeier Eric Director | Grant | Stock Option (Right to Buy) | — | +35K | 34,843 0.05% of shares | low |
| Feb 12, 2026 | Frohlich Tom CEO | Grant | Stock Option (Right to Buy) | — | +473K | 472,500 0.74% of shares | low |
| Feb 12, 2026 | King Andrew James Executive | Grant | Stock Option (Right to Buy) | — | +248K | 247,500 0.39% of shares | low |
| Feb 12, 2026 | Dahms Bradford D. Executive | Grant | Stock Option (Right to Buy) | — | +227K | 226,875 0.36% of shares | low |
| Feb 12, 2026 | Balta Elizabeth Executive | Grant | Stock Option (Right to Buy) | — | +169K | 168,750 0.27% of shares | low |